Clinical trial
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole…
NCT00312598 · University of North Carolina, Chapel Hill, Other · Completed
Key facts
| NCT number | NCT00312598 |
|---|---|
| Title | Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine |
| Official title | Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole |
| Lead sponsor | University of North Carolina, Chapel Hill, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 30 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Apr 10, 2006 |
| Last update posted | Jan 13, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: